However, there are also dose-independent genetic risk factors as evidenced by the association of the XRCC1 (R399Q) DNA repair gene polymorphism with increased risk of telangiectasia irrespective of the patient having received a boost. The gene discussed is XRCC1; the disease is telangiectasis.